13F filer · CIK 1652044 ↗
Alphabet Inc.
You are looking at Q4 2025. See the latest, Q2 2026 →
Reported value
$2.58B
+7.1% on the quarter before
Positions
29
0 new · 8 sold out
Top 10
92.8%
of the value
Est. gain
+$450.5M
on stocks held all quarter
Est. return
+21.2%
on those stocks since Q3 2025
Positions as of Dec 31, 2025, from Alphabet Inc.'s 13F filing with the SEC. A 13F lists a manager's US-listed stocks and options at a quarter end and is filed up to 45 days later, so the fund may hold something else today. It leaves out short positions, cash and holdings outside the US.
Portfolio at a glance
- New
- Added
- Cut
- Same
- Options
Each tile is a position, sized by its share, colored by what the fund did with it since Q3 2025. Striped tiles are options.
Largest buys
Since Q3 2025, by estimated size: the change in shares at the quarter-end price, since a 13F gives no trade prices. Percentages are the position's share of the portfolio, before and after.
- Monte Rosa Therapeutics Inc~$202,907Added · 0.5% → 0.5%+12,941 shares
Largest sells
Since Q3 2025, by estimated size: the change in shares at the quarter-end price, since a 13F gives no trade prices. Percentages are the position's share of the portfolio, before and after.
- Metsera Inc~$198.0MSold out · 8.2% → 0.0%−3,783,528 shares
- Revolution Medicines Inc~$62.8MCut · 8.0% → 10.3%−788,175 shares
- Maze Therapeutics Inc~$42.4MCut · 2.6% → 2.2%−1,023,888 shares
- Dianthus Therapeutics Inc~$8.2MSold out · 0.3% → 0.0%−208,697 shares
- Foghorn Therapeutics Inc~$2.4MSold out · 0.1% → 0.0%−500,901 shares
- Taysha Gene Therapies Inc~$2.1MSold out · 0.1% → 0.0%−640,882 shares
- Tscan Therapeutics Inc~$2.0MSold out · 0.1% → 0.0%−1,077,080 shares
- Barinthus Biotherapeutics Pl~$1.9MSold out · 0.1% → 0.0%−1,513,644 shares
- Fractyl Health Inc~$1.1MSold out · 0.0% → 0.0%−662,584 shares
- Alector Inc~$520,563Sold out · 0.0% → 0.0%−175,866 shares
Holdings
As of Dec 31, 2025. Changes are in shares against Sep 30, 2025, so a price move alone never reads as a buy or a sale.
| Holding | Value | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Ast Spacemobile IncCOM CL A · shares 0% · price +48.0% | 25.2% | $649.6M | +$210.6M | ||||||||
| Planet Labs PbcCOM CL A · shares 0% · price +51.9% | 24.4% | $629.9M | +$215.3M | ||||||||
| Revolution Medicines IncCOM · shares −19% · price +70.6% | 10.3% | $266.4M | +$110.2M | ||||||||
| Arm Holdings PlcSPONSORED ADS · shares 0% · price −22.7% | 8.3% | $214.3M | −$63.1M | ||||||||
| Freshworks IncCLASS A COM · shares 0% · price +4.1% | 7.7% | $198.5M | +$7.8M | ||||||||
| UiPathCL A · shares 0% · price +22.5% | 4.5% | $115.3M | +$21.2M | ||||||||
| Gitlab IncCLASS A COM · shares 0% · price −16.7% | 4.0% | $102.3M | −$20.6M | ||||||||
| Tempus AICL A · shares 0% · price −26.8% | 3.6% | $91.6M | −$33.6M | ||||||||
| Dexcom IncCOM · shares 0% · price −1.4% | 2.7% | $68.8M | −$953,982 | ||||||||
| Maze Therapeutics IncCOM · shares −42% · price +59.8% | 2.2% | $57.5M | +$21.5M | ||||||||
| Prime Medicine IncCOM · shares 0% · price −37.4% | 2.2% | $57.5M | −$34.3M | ||||||||
| Bridgebio Oncology TherapeutCOM NEW · shares 0% · price +8.1% | 1.4% | $35.3M | +$2.7M | ||||||||
| Relay Therapeutics IncCOM · shares 0% · price +62.1% | 0.51% | $13.3M | +$5.1M | ||||||||
| Vera Therapeutics IncCL A · shares 0% · price +74.3% | 0.47% | $12.2M | +$5.2M | ||||||||
| Monte Rosa Therapeutics IncCOM · shares +1.8% · price +5.8% | 0.45% | $11.7M | +$629,527 | ||||||||
| Sana Biotechnology IncCOM · shares 0% · price +14.6% | 0.44% | $11.4M | +$1.5M | ||||||||
| Lyell Immunopharma IncCOM NEW · shares 0% · price +89.5% | 0.35% | $9.0M | +$4.3M | ||||||||
| Beam Therapeutics IncCOM · shares 0% · price +14.2% | 0.35% | $8.9M | +$1.1M | ||||||||
| Figma IncCLASS A COM STK · shares 0% · price −28.0% | 0.31% | $8.1M | −$3.1M | ||||||||
| Oscar Health IncCL A · shares 0% · price −24.1% | 0.27% | $6.9M | −$2.2M | ||||||||
| Genedx Holdings CorpCOM · shares 0% · price +20.7% | 0.11% | $3.0M | +$506,910 | ||||||||
| Exact Sciences CorpCOM · shares 0% · price +85.6% | 0.09% | $2.4M | +$1.1M | ||||||||
| Spero Therapeutics IncCOM · shares 0% · price +23.9% | 0.08% | $2.1M | +$400,490 | ||||||||
| Autolus Therapeutics PlcSPON ADS · shares 0% · price +22.1% | 0.05% | $1.4M | +$251,374 | ||||||||
| Hyperfine IncCOM CL A · shares 0% · price −32.4% | 0.03% | $880,746 | −$422,398 | ||||||||
| Total · 29 positions | 100% | $2.58B | +$450.5M |
Price is a stock's reported value over its shares at the quarter end. The estimated gain is the shares held at both quarter ends times the change in that price: shares bought or sold during the quarter add nothing, options are left out, and a stock split is read into the earlier share count and price.
What made money
From Q3 2025 to Q4 2025: 29 stocks held throughout, up $450.5M (+21.2%).
- Planet Labs Pbc+$215.3M+52%
- Ast Spacemobile Inc+$210.6M+48%
- Revolution Medicines Inc+$110.2M+71%
- Maze Therapeutics Inc+$21.5M+60%
- UiPath+$21.2M+22%
- Figma Inc−$3.1M−28%
- Gitlab Inc−$20.6M−17%
- Tempus AI−$33.6M−27%
- Prime Medicine Inc−$34.3M−37%
- Arm Holdings Plc−$63.1M−23%
Estimated as in the holdings table: shares held at both quarter ends times the change in price; options left out, 1 split read into the share counts.
Reported value by quarter
The total value of each quarter's 13F at that quarter end. It moves with prices as well as with buying and selling. Pick a quarter to see what the fund held then.
Every quarter's filing
| Quarter | Reported value | Filing | |
|---|---|---|---|
| Q2 2026 | Aug 7, 2026 | $99.08B+2,367% | SEC ↗ |
| Q1 2026 | May 8, 2026 | $4.02B+56% | SEC ↗ |
| Q4 2025 | Feb 13, 2026 | $2.58B+7% | SEC ↗ |
| Q3 2025 | Nov 7, 2025 | $2.41B+13% | SEC ↗ |
| Q2 2025 | Aug 1, 2025 | $2.14B+35% | SEC ↗ |
| Q1 2025 | May 2, 2025 | $1.58B−8% | SEC ↗ |
| Q4 2024 | Feb 7, 2025 | $1.72B−7% | SEC ↗ |
| Q3 2024 | Nov 8, 2024 | $1.84B−7% | SEC ↗ |
| Q2 2024 | Aug 2, 2024 | $1.97B−21% | SEC ↗ |
| Q1 2024 | May 3, 2024 | $2.51B+17% | SEC ↗ |
| Q4 2023 | Feb 9, 2024 | $2.16B+39% | SEC ↗ |
| Q3 2023 | Nov 13, 2023 | $1.56B−16% | SEC ↗ |
| Q2 2023 | Aug 4, 2023 | $1.86B+3% | SEC ↗ |
| Q1 2023 | May 11, 2023 | $1.80B+5% | SEC ↗ |
| Q4 2022 | Feb 14, 2023 | $1.72B−12% | SEC ↗ |
| Q3 2022 | Nov 15, 2022 | $1.96B+6% | SEC ↗ |
| Q2 2022 | Nov 15, 2022 | $1.84B−40% | SEC ↗ |
| Q1 2022 | Nov 15, 2022 | $3.08B−26% | SEC ↗ |
| Q4 2021 | Nov 15, 2022 | $4.14B−2% | SEC ↗ |
| Q3 2021 | Nov 15, 2022 | $4.22B−14% | SEC ↗ |
| Q2 2021 | Nov 15, 2022 | $4.91B+98% | SEC ↗ |
| Q1 2021 | Nov 15, 2022 | $2.48B+19% | SEC ↗ |
| Q4 2020 | Nov 15, 2022 | $2.08B−2% | SEC ↗ |
| Q3 2020 | Nov 15, 2022 | $2.13B−2% | SEC ↗ |
| Q2 2020 | Nov 15, 2022 | $2.17B+42% | SEC ↗ |
| Q1 2020 | Nov 15, 2022 | $1.52B−8% | SEC ↗ |
| Q4 2019 | Nov 15, 2022 | $1.65B−50% | SEC ↗ |
| Q3 2019 | Nov 15, 2022 | $3.33B−37% | SEC ↗ |
| Q2 2019 | Nov 15, 2022 | $5.27B+172% | SEC ↗ |
| Q1 2019 | Nov 15, 2022 | $1.94B+129% | SEC ↗ |
| Q4 2018 | Nov 15, 2022 | $845.8M−19% | SEC ↗ |
| Q3 2018 | Nov 15, 2022 | $1.04B−12% | SEC ↗ |
| Q2 2018 | Nov 15, 2022 | $1.19B+94% | SEC ↗ |
| Q1 2018 | Nov 15, 2022 | $614.8M+67% | SEC ↗ |
| Q4 2017 | Nov 15, 2022 | $368.6M+7% | SEC ↗ |
| Q3 2017 | Nov 15, 2022 | $344.0M−1% | SEC ↗ |
| Q2 2017 | Nov 15, 2022 | $347.4M+10% | SEC ↗ |
| Q1 2017 | Nov 15, 2022 | $316.8M+8% | SEC ↗ |
| Q4 2016 | Nov 15, 2022 | $292.8M+6% | SEC ↗ |
| Q3 2016 | Nov 15, 2022 | $275.2M+31% | SEC ↗ |
| Q2 2016 | Nov 15, 2022 | $209.8M−14% | SEC ↗ |
| Q1 2016 | Nov 15, 2022 | $242.9M | SEC ↗ |